Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.
Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic options for...
Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination difficulties. SCA1...
Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to significant changes...
